Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a publicly held clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. Their approach targets the DNA polymerase IIIC enzyme and their pipeline includes candidates targeting Gram-positive bacteria such as MRSA, VRE, and PRSP. The company is actively engaged in advancing its research and development efforts, with recent financial results and cash flow statements indicating ongoing operations and financing activities.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Clinical-stage DNA polymerase IIIC inhibitor (clinical candidate)
A clinical-stage small-molecule antibiotic candidate designed to inhibit bacterial DNA polymerase IIIC/PolC for treatment of Clostridioides difficile infection and other Gram-positive infections.
Early-stage Gram-positive antibiotic candidate portfolio
Pipeline of discovery-stage small-molecule antibiotic candidates directed at Gram-positive bacteria including MRSA, VRE and Streptococcus species.
Clinical-stage DNA polymerase IIIC inhibitor (clinical candidate)
A clinical-stage small-molecule antibiotic candidate designed to inhibit bacterial DNA polymerase IIIC/PolC for treatment of Clostridioides difficile infection and other Gram-positive infections.
Early-stage Gram-positive antibiotic candidate portfolio
Pipeline of discovery-stage small-molecule antibiotic candidates directed at Gram-positive bacteria including MRSA, VRE and Streptococcus species.
Services
Sponsored research and collaborative agreements with academic and clinical partners to generate target validation, efficacy and microbiome data supporting development of antibiotic candidates.
Preparation and delivery of scientific posters, oral presentations and publications to communicate nonclinical and clinical study results to scientific and clinical audiences.
Sponsored research and collaborative agreements with academic and clinical partners to generate target validation, efficacy and microbiome data supporting development of antibiotic candidates.
Preparation and delivery of scientific posters, oral presentations and publications to communicate nonclinical and clinical study results to scientific and clinical audiences.
Expertise Areas
- Enzyme-targeted antibiotic discovery
- Preclinical microbiology and in vivo pharmacology against Gram-positive pathogens
- Clinical trial management for anti-infectives (including Phase 2 randomized, double‑blind studies)
- Microbiome sequencing and comparative analysis in drug development
Key Technologies
- Target-based small-molecule inhibitor discovery
- In vitro antibacterial susceptibility assays
- Preclinical animal infection models
- Microbiome sequencing and comparative bioinformatics